

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Virtus Health Limited
<b>ABN</b> 80 129 643 492

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Susan Channon
<b>Date of last notice</b>	7 December 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ryletro Pty Ltd - Ms Channon is a shareholder and director of Ryletro Pty Ltd.
<b>Date of change</b>	21 November 2018
<b>No. of securities held prior to change</b>	<b>Direct interests:</b> 154,061 Performance Rights  <b>Indirect interests:</b> 354,881 Fully Paid Ordinary shares NIL Performance Rights (following lapse of 36,472 Performance Rights under the Virtus Health Limited Executive Option Plan, approved by shareholders at the Annual General Meeting held on 29 October 2014).
<b>Class</b>	Performance Rights
<b>Number acquired</b>	<b>Direct interests:</b> 56,441 Performance Rights
<b>Number disposed</b>	<b>Direct interests:</b> 58,825 Performance Rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Direct interests:</b> 151,677 Performance Rights  <b>Indirect interests:</b> 354,881 Fully Paid Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Performance Rights under the Virtus Health Limited Executive Option Plan, approved by shareholders at the Annual General Meeting held on 21 November 2018 and lapse of Performance Rights under the Virtus Health Limited Executive Option Plan, approved by shareholders at the Annual General Meeting held on 28 October 2015.

---

+ See chapter 19 for defined terms.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Not applicable
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

Date of notice: 28 November 2018

---

<sup>+</sup> See chapter 19 for defined terms.